There was only one study [14] (Figure 7A) result (HR = 1.79, 95% CI = 1.08-2.99) describing the OS-breast cancer, indicating significantly detrimental effect for breast cancer treated with IGF-1R inhibitors. This evidence concerns the gene IGF1R and breast cancer.